| 2025-08-08 | +33.8% | legal | Seeking Alpha | Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth |
| 2025-08-08 | +33.8% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript |
| 2023-12-28 | -31.6% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-11-11 | +31.3% | expansion | Stock Titan | CytoSorbents Expands Into India Through Strategic Converge Biotech Partnership - Stock Titan |
| 2022-12-29 | +28.7% | legal | SEC EDGAR | CTSO 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-11-09 | +25.6% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript |
| 2025-08-20 | -21.2% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-11-07 | -20.7% | earnings | Seeking Alpha | Cytosorbents GAAP EPS of -$0.08 misses by $0.02, revenue of $9.39M misses by $0.79M |
| 2024-11-07 | -20.7% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2022-11-03 | -19.6% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2022-04-29 | +19.3% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-07-05 | +16.7% | legal | SEC EDGAR | CTSO 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-07-02 | -16.7% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2021-10-13 | -15.6% | legal | SEC EDGAR | CTSO 8-K: 2.02, 8.01 (SEC Filing) |
| 2023-07-11 | +14.4% | legal | SEC EDGAR | CTSO 8-K: 5.02 (SEC Filing) |
| 2023-05-02 | +13.1% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2026-03-25 | -12.6% | earnings | Associated Press Finance | CytoSorbents: Q4 Earnings Snapshot |
| 2026-03-25 | -12.6% | news | PR Newswire | CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-03-25 | -12.6% | legal | Seeking Alpha | Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth |
| 2026-03-25 | -12.6% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript |
| 2026-03-25 | -12.6% | earnings | Seeking Alpha | Cytosorbents Non-GAAP EPS of -$0.07, revenue of $9.22M beats by $0.01M |
| 2026-03-25 | -12.6% | legal | SEC EDGAR | CTSO 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-08-02 | -12.3% | legal | SEC EDGAR | CTSO 8-K: 1.01, 2.02, 8.01 (SEC Filing) |
| 2024-08-14 | +11.9% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2023-12-11 | +11.7% | legal | SEC EDGAR | CTSO 8-K: 1.01, 8.01 (SEC Filing) |
| 2023-11-09 | -11.3% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2025-01-03 | +11.2% | earnings | Seeking Alpha | CytoSorbents sees Q4 product revenue growth of 22% to 25% Y/Y |
| 2025-01-03 | +11.2% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2025-03-04 | +10.8% | legal | SEC EDGAR | CTSO 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-12-13 | +10.8% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-01-13 | +10.6% | legal | SEC EDGAR | CTSO 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-08-02 | -10.5% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2023-04-26 | -10.4% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2021-05-05 | -10.3% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2025-05-15 | +10.3% | legal | Seeking Alpha | Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025 |
| 2025-05-15 | +10.3% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript |
| 2025-08-07 | +10.2% | earnings | Seeking Alpha | Cytosorbents Non-GAAP EPS of -$0.05, revenue of $9.6M beats by $0.38M |
| 2025-08-07 | +10.2% | legal | SEC EDGAR | CTSO 8-K: 2.01 and (SEC Filing) |
| 2024-10-01 | -9.8% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-10-01 | -9.8% | legal | SEC EDGAR | CTSO 8-K: 2.02, 8.01 (SEC Filing) |
| 2023-02-01 | +9.7% | legal | SEC EDGAR | CTSO 8-K: 2.02, 8.01 (SEC Filing) |
| 2022-11-16 | -9.4% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-05-01 | -9.1% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-04-17 | +9.1% | expansion | Stock Titan | CytoSorbents Taps Former Stryker, Vaxxinity Executive to Lead Financial Operations Ahead of Key Product Launch - Stock Titan |
| 2022-05-04 | -9.0% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2022-01-18 | +9.0% | legal | SEC EDGAR | CTSO 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-01-06 | +8.4% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2026-03-26 | -8.2% | earnings | Motley Fool | Cytosorbents (CTSO) Q4 2025 Earnings Transcript |
| 2026-03-26 | -8.2% | earnings | Moby | Cytosorbents Corporation Q4 2025 Earnings Call Summary |
| 2026-03-26 | -8.2% | earnings | GuruFocus.com | CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... |
| 2025-05-13 | -7.9% | earnings | Seeking Alpha | Cytosorbents Q1 Earnings Preview |
| 2022-03-17 | +7.5% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-08-01 | +7.3% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2026-04-02 | +7.3% | earnings | Seeking Alpha | Cytosorbents Corporation 2025 Q4 - Results - Earnings Call Presentation |
| 2026-04-02 | +7.3% | earnings | Seeking Alpha | Cytosorbents Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTSO) 2026-04-02 - Seeking Alpha |
| 2026-04-02 | +7.3% | news | Stock Titan | Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan |
| 2023-09-12 | -7.3% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-03-21 | -7.0% | legal | SEC EDGAR | CTSO 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-08-06 | +7.0% | earnings | Zacks Investment Research | What date does Cytosorbents's (CTSO) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2025-04-21 | +6.6% | news | Seeking Alpha | CytoSorbents gets $1.7M from New Jersey business tax certificate transfer program |
| 2025-04-04 | +6.1% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-12-15 | -6.0% | legal | Seeking Alpha | Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript |
| 2023-09-01 | -6.0% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2025-06-24 | -5.9% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-01-24 | +5.8% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-03-05 | +5.7% | earnings | Seeking Alpha | Cytosorbents Q4 Earnings Preview |
| 2022-04-14 | -5.7% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-03-08 | -5.7% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2021-09-14 | -5.4% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-11-13 | +5.0% | earnings | Seeking Alpha | Cytosorbents Non-GAAP EPS of -$0.04, revenue of $9.5M misses by $0.52M |
| 2025-11-13 | +5.0% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | +5.0% | news | PR Newswire | CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire |
| 2025-11-13 | +5.0% | earnings | simplywall.st | Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower - simplywall.st |
| 2025-11-13 | +5.0% | earnings | Yahoo Finance | CytoSorbents Corp (CTSO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance |
| 2025-05-26 | -4.9% | news | Intellectia AI | CTSO Forecast — Price Prediction for 2026. Should I Buy CTSO? - Intellectia AI |
| 2022-09-28 | -4.9% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-08-15 | -4.8% | legal | SEC EDGAR | CTSO 8-K: 2.03 and 5.02 (SEC Filing) |
| 2025-05-14 | -4.6% | earnings | Seeking Alpha | Cytosorbents Non-GAAP EPS of -$0.06, revenue of $8.73M misses by $0.28M |
| 2025-05-14 | -4.6% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | +4.1% | news | Zacks Small Cap Research | CTSO: CytoSorbents Reports Strong 4th Quarter and Full Year 2025 Results |
| 2021-07-06 | +4.0% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-11-17 | -4.0% | earnings | Seeking Alpha | Cytosorbents Corporation 2025 Q3 - Results - Earnings Call Presentation |
| 2026-04-08 | -4.0% | news | Xã Thanh Hà | What limits growth of Cytosorbents (CTSO) Stock | Price at $0.63, Up 3.44% - Institutional Flow - Xã Thanh Hà |
| 2022-04-07 | -3.8% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2026-04-22 | +3.7% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CTSO (Cytosorbents Corporation) shares rise 8.2 percent despite Q4 2025 earnings landing below consensus analyst estimates. - High Volatility - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-12-09 | -3.7% | legal | SEC EDGAR | CTSO 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-05-09 | +3.7% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2023-07-19 | -3.5% | legal | SEC EDGAR | CTSO 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-03-19 | +3.5% | expansion | PR Newswire | CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 |
| 2026-03-19 | +3.5% | news | Stock Titan | CytoSorbents says new ICU swap system cuts workload in critical care - Stock Titan |
| 2021-10-15 | -3.4% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-08-01 | +3.3% | legal | SEC EDGAR | CTSO 8-K: 8.01 (SEC Filing) |
| 2022-10-06 | +3.2% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2022-06-01 | -3.2% | legal | SEC EDGAR | CTSO 8-K: 8.01 (SEC Filing) |
| 2021-10-21 | -3.2% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-08-06 | -3.1% | earnings | Seeking Alpha | Cytosorbents Q2 Earnings Preview |
| 2021-10-08 | -3.1% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-11-12 | -3.0% | earnings | Seeking Alpha | Cytosorbents Q3 Earnings Preview |
| 2026-03-05 | +2.9% | news | PR Newswire | CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2021-08-04 | +2.8% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2023-09-19 | +2.6% | legal | SEC EDGAR | CTSO 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-04-15 | +2.5% | news | Stock Titan | Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan |
| 2026-04-21 | -2.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Cytosorbents (CTSO) Stock: Near Support? (Volatility Increases) 2026-04-20 - Continuation Pattern - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-21 | -2.5% | news | Cổng thông tin điện tử tỉnh Lào Cai | Cytosorbents (CTSO) Stock: Near Support? (Volatility Increases) 2026-04-20 - Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2021-09-10 | -2.5% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-04-28 | +2.5% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-01-20 | +2.5% | legal | SEC EDGAR | CTSO 8-K: 1.01 and (SEC Filing) |
| 2022-06-03 | +1.9% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2023-04-20 | -1.8% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2024-01-17 | -1.8% | legal | SEC EDGAR | CTSO 8-K: 3.01, 8.01 (SEC Filing) |
| 2024-08-16 | +1.8% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2021-11-04 | +1.6% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2021-12-30 | +1.5% | legal | SEC EDGAR | CTSO 8-K: 1.01 and (SEC Filing) |
| 2024-11-06 | +1.5% | earnings | Seeking Alpha | Cytosorbents Q3 2024 Earnings Preview |
| 2025-02-25 | +1.4% | legal | Stock Titan | CytoSorbents Secures $1.6M Capital Injection - Will This Fuel Their FDA Application Success? - Stock Titan |
| 2025-03-28 | +1.4% | earnings | Seeking Alpha | Cytosorbents FY Earnings Preview |
| 2022-09-03 | -1.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Cytosorbents (CTSO) - Zacks Investment Research |
| 2021-12-21 | -1.2% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-04-03 | +1.1% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2021-09-01 | +1.1% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2022-04-05 | +1.0% | legal | SEC EDGAR | CTSO 8-K: 5.02 and (SEC Filing) |
| 2024-10-22 | +1.0% | legal | Seeking Alpha | CytoSorbents rises as FDA accepts application for device to reduce bleeding risk in bypass surgery |
| 2025-03-31 | -1.0% | news | Seeking Alpha | Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR |
| 2025-03-31 | -1.0% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript |
| 2025-03-31 | -1.0% | earnings | Seeking Alpha | Cytosorbents Non-GAAP EPS of -$0.03, revenue of $9.15M |
| 2025-03-31 | -1.0% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2025-09-16 | -0.9% | legal | SEC EDGAR | CTSO 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-04-23 | -0.9% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CTSO (Cytosorbents Corporation) posts 4.1 percent Q4 2025 revenue growth as shares edge higher despite a wide EPS miss. - Macro Risk - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-08-20 | +0.8% | legal | SEC EDGAR | CTSO 8-K: 1.01 (SEC Filing) |
| 2023-03-09 | -0.8% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |
| 2026-04-03 | +0.7% | news | The Globe and Mail | CytoSorbents Receives Nasdaq Extension to Regain Compliance - The Globe and Mail |
| 2026-03-24 | -0.7% | earnings | Seeking Alpha | Cytosorbents Q4 Earnings Preview |
| 2023-09-27 | -0.6% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2023-07-07 | +0.6% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2025-11-14 | -0.6% | earnings | Seeking Alpha | Cytosorbents outlines cash flow breakeven targets for Q1 2026 through workforce and cost restructuring |
| 2025-11-14 | -0.6% | earnings | Seeking Alpha | Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript |
| 2022-02-01 | +0.5% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-02-12 | +0.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-02-14 | -0.3% | analyst | Simply Wall St. | Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long |
| 2026-02-14 | -0.3% | analyst | Yahoo Finance | Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance |
| 2023-04-06 | +0.1% | legal | SEC EDGAR | CTSO 8-K: 1.01, 5.02 (SEC Filing) |
| 2021-08-12 | -0.1% | legal | SEC EDGAR | CTSO 8-K: 8.01 and (SEC Filing) |
| 2024-03-15 | -0.0% | legal | SEC EDGAR | CTSO 8-K: 2.02 and (SEC Filing) |